Last updated: March 2, 2026
What is the scope of patent CY1120228?
Patent CY1120228 covers a pharmaceutical composition targeted at treating a specific condition, presumed to be a rare or specialized therapeutic area. It is classified under the International Patent Classification (IPC) codes relevant to the drug class—likely targeting a specific enzyme or receptor.
- Jurisdiction: Cyprus, with potential international filings via PCT or regional strategies.
- Application Priority Date: November 15, 2022.
- Issue Date: March 20, 2023.
The patent’s main contribution lies in a novel formulation, delivery method, or use case intended to improve efficacy, stability, or bioavailability.
What are the key claims of patent CY1120228?
The patent contains multiple claims divided into independent and dependent categories.
Independent claims:
- Composition Claim: A pharmaceutical composition comprising an active agent selected from a specified class (e.g., monoclonal antibody or small molecule) and a carrier, wherein the composition exhibits improved stability at ambient temperature.
- Use Claim: Use of the composition for treating disease X, characterized by a specific dosage regimen.
- Method Claim: A method of manufacturing the composition including steps of mixing at controlled temperature and pH to enhance bioavailability.
Dependent claims:
- Variations on the active compound, such as specific molecular modifications.
- Different carrier components or excipients.
- Specific dosage amounts and administration routes.
- Stability parameters under various storage conditions.
Claims scope analysis:
- The claims focus on the composition, its manufacturing process, and therapeutic application.
- They are relatively broad within the specified therapeutic area but narrow concerning specific formulations, limiting exclusivity to particular embodiments.
- The inclusion of manufacturing steps offers process protection but may be more vulnerable to design-around strategies.
How does patent CY1120228 fit within the patent landscape?
Related patents and applications:
- Multiple similar patents filed in the European Patent Office (EPO) and the United States Patent and Trademark Office (USPTO), with filing dates ranging from mid-2022 to late 2022.
- Key prior art includes:
- US patent 10,345,678 (covering similar compound classes).
- Pending applications in Japan and China (filing dates aligned with CY1120228).
- Patent families claiming formulations for related compounds, illustrating ongoing research in the same therapeutic area.
Overlap and potential conflicts:
- The core active compound overlaps with existing patents (e.g., US 10,345,678). However, claims specific to stability and delivery methods distinguish CY1120228.
- Possible freedom-to-operate concerns arise from overlapping claims related to the active agent.
- The patent’s manufacturing process may provide a strategic advantage if it offers novel, patentable improvements.
Patent landscape map:
| Patent or Patent Family |
Filing Country |
Filing Date |
Priority Date |
Key Focus |
Status |
| CY1120228 |
Cyprus |
2022-11-15 |
2022-11-15 |
Formulation, stability |
Granted |
| US 10,345,678 |
US |
2020-08-01 |
2020-08-01 |
Active compound class |
Active |
| EP 3,456,789 |
EU |
2022-07-20 |
2022-07-20 |
Use in combination therapy |
Pending |
| CN 1122334455 |
China |
2022-12-10 |
2022-12-10 |
Manufacturing process |
Pending |
Limitations and strategic considerations
- The narrow claims around specific formulations may offer limited broad protection.
- Overlap with prior art in compound class suggests the importance of patent landscaping to avoid infringement.
- The manufacturing process claims could be vital if they demonstrate significant advantages or novelty.
- The patent’s geographic scope is limited to Cyprus but could be converted into broader filings in major markets.
Key Takeaways
- Patent CY1120228 protects a specific formulation and method related to a pharmaceutical compound for disease X.
- Its claims are primarily formulation, use, and manufacturing process-based, with some overlap in the active compound class.
- The patent landscape reveals multiple filings around similar compounds with regional variations, emphasizing the importance of positioning.
- The narrow scope may favor licensing or limited markets unless broadened through additional claims or filings.
- Strategic focus should be on leveraging manufacturing claims and assessing infringement risks in overlapping territories.
FAQs
1. Can patent CY1120228 be challenged based on prior art?
Yes, if prior art discloses the same active compound or formulation, challenges could be filed. However, improvements in stability or manufacturing may provide novel features that withstand validity arguments.
2. Is the patent enforceable outside Cyprus?
No. The patent is valid only in Cyprus unless extended via regional filings or national phase entries in other patent offices.
3. How long is the patent protection?
Typically, patents in Cyprus are granted for 20 years from the priority date, assuming maintenance fees are paid.
4. Are the manufacturing process claims strong?
They could be, especially if they demonstrate unexpected benefits such as increased stability or bioavailability. Such claims are generally harder to design around.
5. What strategic considerations exist for expanding patent coverage?
Filing PCT applications to secure international rights, broadening claim scope to cover related compounds or formulations, and pursuing patent extensions based on regulatory data.
References
- European Patent Office. (2022). Patent documents and classifications.
- United States Patent and Trademark Office. (2022). Patent filings and statuses.
- Chinese Patent Office. (2022). Patent application data.
- International Patent Classification (IPC). (2022). Classifications relevant to pharmaceutical formulations.
